238 related articles for article (PubMed ID: 16370386)
1. Therapeutic strategies for the treatment of neuroblastoma.
Izbicka E; Izbicki T
Curr Opin Investig Drugs; 2005 Dec; 6(12):1200-14. PubMed ID: 16370386
[TBL] [Abstract][Full Text] [Related]
2. Molecularly guided therapy of neuroblastoma: a review of different approaches.
Tonini GP; Pistoia V
Curr Pharm Des; 2006; 12(18):2303-17. PubMed ID: 16787256
[TBL] [Abstract][Full Text] [Related]
3. Role of the MRP1/ABCC1 multidrug transporter protein in cancer.
Munoz M; Henderson M; Haber M; Norris M
IUBMB Life; 2007 Dec; 59(12):752-7. PubMed ID: 18085475
[TBL] [Abstract][Full Text] [Related]
4. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
Paffhausen T; Schwab M; Westermann F
Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
[TBL] [Abstract][Full Text] [Related]
5. Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.
Cabanillas Stanchi KM; Bruchelt G; Handgretinger R; Holzer U
Cancer Biol Ther; 2015; 16(9):1353-63. PubMed ID: 26177922
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
7. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic approaches to advanced prostate cancer.
Armstrong AJ; Carducci MA
Clin Adv Hematol Oncol; 2005 Apr; 3(4):271-82. PubMed ID: 16167000
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenesis in neuroblastoma.
Ribatti D
Crit Rev Oncol Hematol; 2013 Jun; 86(3):212-21. PubMed ID: 23273512
[TBL] [Abstract][Full Text] [Related]
11. Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P; Cañete A; Castel V
Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy of neuroblastoma.
George RE; Diller L; Bernstein ML
Expert Opin Pharmacother; 2010 Jun; 11(9):1467-78. PubMed ID: 20408767
[TBL] [Abstract][Full Text] [Related]
13. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma.
Liontas A; Yeger H
Anticancer Res; 2004; 24(2B):987-98. PubMed ID: 15161054
[TBL] [Abstract][Full Text] [Related]
14. DNA-damaging drug-induced apoptosis sensitized by N-myc in neuroblastoma cells.
Li T; Wang L; Ke XX; Gong XY; Wan JH; Hao XW; Xu M; Xiang Z; Cui ZB; Cui H
Cell Biol Int; 2012 Apr; 36(4):331-7. PubMed ID: 21929510
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
[TBL] [Abstract][Full Text] [Related]
16. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
17. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models.
Morowitz MJ; Barr R; Wang Q; King R; Rhodin N; Pawel B; Zhao H; Erickson SA; Sheppard GS; Wang J; Maris JM; Shusterman S
Clin Cancer Res; 2005 Apr; 11(7):2680-5. PubMed ID: 15814649
[TBL] [Abstract][Full Text] [Related]
18. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.
Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G
Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037
[TBL] [Abstract][Full Text] [Related]
19. Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification.
Kushner BH; LaQuaglia MP; Modak S; Cheung NK
Med Pediatr Oncol; 2003 Jul; 41(1):80-2. PubMed ID: 12764755
[No Abstract] [Full Text] [Related]
20. How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers.
Maris JM
Pediatr Blood Cancer; 2005 Dec; 45(7):869-70. PubMed ID: 16206200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
